Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
LBP408: 0.63 g/t Au over 112.8 m including 0.74 g/t Au over 73.2 mLBP418: 0.50 g/t Au over 42.7 m and 1.00 g/t Au over 24.4 m VANCOUVER, British Columbia, Nov. 16, 2021 (GLOBE NEWSWIRE) --...
-
Ottawa, Nov. 16, 2021 (GLOBE NEWSWIRE) -- In 2020, the power distribution component market valued at US$ 102.10 billion and it is expected to grow at a CAGR of 6.1% during the forecast period owing...
-
16 November 2021, 11:00 CET With reference to Article 19(3) of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse (Market Abuse Regulations),...
-
Zurich, Switzerland, Nov. 16, 2021 (GLOBE NEWSWIRE) -- Zurich, Switzerland, 16 November, 2021 – Further to its press release on October 13, 2021, announcing its evolution to Hitachi Energy, the...
-
CAMBRIDGE, United Kingdom and NEW YORK, Nov. 16, 2021 (GLOBE NEWSWIRE) -- Artios Pharma Limited (Artios), a leading biotech company pioneering the development of novel small molecule therapeutics...
-
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, INTO OR WITHIN CANADA, AUSTRALIA, NEW ZEALAND, SOUTH AFRICA, HONG KONG, JAPAN OR ANY OTHER JURISDICTION IN...
-
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, INTO OR WITHIN CANADA, AUSTRALIA, NEW ZEALAND, SOUTH AFRICA, HONG KONG, JAPAN OR ANY OTHER JURISDICTION IN...
-
16 November 2021Interim Results Statement for the six months ended 30 September 2021 Record fundraising and multiple drivers of future compounding growth Highlights Strong momentum continuing...
-
In 2022 AS Ekspress Grupp will publish its consolidated financial results and quarterly results of digital subscriptions according to the schedule below. DateEvent12th January...
-
NANTES, France, Nov. 16, 2021 (GLOBE NEWSWIRE) -- November 16, 2021, 7:30 a.m. CET - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) presented new clinical and translational data on...